EGFR and non-small cell lung carcinoma: Short in-frame deletions in exon 19 (19-Del) and point mutations in EGFR exon 21 p.L858R are the most common activating mutations in EGFR, accounting for approximately 90% of all EGFR mutations in NSCLC [5, 6].